TY - JOUR
T1 - Deanol in the management of involuntary movement disorders
T2 - A review
AU - Casey, D. E.
PY - 1977/12/1
Y1 - 1977/12/1
N2 - Deanol, because of its ability to increase CNS acetylcholine, recently has been used to treat the dyskinetic symptoms associated with tardive dyskinesia, levodopa-induced dyskinesias, Huntington's disease, and a few other uncommon dyskinesias. Although firm conclusions cannot be drawn because the majority of investigations were not conducted under double-blind placebo-controlled conditions, some trends may be inferred from the available data. Overall, 25%-50% of the patients with tardive dyskinesia or levodopa-induced dyskinesias improved while taking deanol. Results are less encouraging in Huntington's disease as only a small proportion of patients have benefited from treatment with deanol. The individual reports of the use of deanol for senile dyskinesias, blepharospasm, congenital athetosis, Tourette's syndrome, and oromandibular dystonia are interesting, but the number of cases which have been treated and which show improvement are too few to note trends.
AB - Deanol, because of its ability to increase CNS acetylcholine, recently has been used to treat the dyskinetic symptoms associated with tardive dyskinesia, levodopa-induced dyskinesias, Huntington's disease, and a few other uncommon dyskinesias. Although firm conclusions cannot be drawn because the majority of investigations were not conducted under double-blind placebo-controlled conditions, some trends may be inferred from the available data. Overall, 25%-50% of the patients with tardive dyskinesia or levodopa-induced dyskinesias improved while taking deanol. Results are less encouraging in Huntington's disease as only a small proportion of patients have benefited from treatment with deanol. The individual reports of the use of deanol for senile dyskinesias, blepharospasm, congenital athetosis, Tourette's syndrome, and oromandibular dystonia are interesting, but the number of cases which have been treated and which show improvement are too few to note trends.
UR - http://www.scopus.com/inward/record.url?scp=0017762669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017762669&partnerID=8YFLogxK
M3 - Review article
C2 - 145359
AN - SCOPUS:0017762669
VL - 38
SP - 7
EP - 15
JO - Diseases of the Nervous System
JF - Diseases of the Nervous System
SN - 0160-6689
IS - 12 II
ER -